NCT02647879 Treatment as Prevention for Hepatitis C in Iceland
| NCT ID | NCT02647879 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Landspitali University Hospital |
| Condition | Hepatitis C |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-01 |
| Primary Completion | 2021-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-01 with a primary completion date of 2021-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of this study is to test in the Icelandic population the hypothesis that a nationwide treatment program which offers effective treatment to all known cases of Hepatitis C with the aim of halting HCV (Hepatitis C virus) transmission will lead to a reduction in incidence and disease burden associated with chronic HCV infection.
Eligibility Criteria
Inclusion Criteria: * HCV positive subjects 18 years and older, living in Iceland and covered by the Icelandic Health Insurance. Exclusion Criteria: * Age under 18 years * Inability to sign informed consent.
Contact & Investigator
Sigurdur Olafsson, MD
PRINCIPAL INVESTIGATOR
Landspitali University Hospital
Frequently Asked Questions
Who can join the NCT02647879 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatitis C. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02647879 currently recruiting?
Yes, NCT02647879 is actively recruiting participants. Contact the research team at ragnhefr@landspitali.is for enrollment information.
Where is the NCT02647879 trial being conducted?
This trial is being conducted at Reykjavik, Iceland.
Who is sponsoring the NCT02647879 clinical trial?
NCT02647879 is sponsored by Landspitali University Hospital. The principal investigator is Sigurdur Olafsson, MD at Landspitali University Hospital. The trial plans to enroll 1,000 participants.